The Genentech Sales Pitch: Higher Values R Us
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite a blizzard, Genentech attracts more than 300 Wall Street analysts and investors to hear why Roche’s bid undervalues the biotech.